How high can we increase complete remission rate in adult acute myeloid leukemia?

International Journal of Hematology

Volumn 72, Issue 3, 2000, Pages 272-279

  Ohno, Ryuzo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acute myeloid leukemia; Adult; Complete remission rate; Japan Adult Leukemia Study Group; Multicenter study

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE DISEASE; ADULT; HUMAN; MYELOID LEUKEMIA; PATHOLOGY; PATHOPHYSIOLOGY; REMISSION; REVIEW;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOID; REMISSION INDUCTION;

EID: 0034304417     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 1991;337:61-66.
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328: 1002-1006.
3. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000;342:1069-1076.
4. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000;92:225-233.
5. Peters W, Rosner G, Vredenburgh J, et al. A prospective randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAP in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB9082/SWOG9114/NCIC MA-13 [abstract]. Proc Am Soc Clin Oncol. 1999;18:1a.
6. The Scandinavian Breast Cancer Study Group 9401. Results from randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy [abstract]. Proc Am Soc Clin Oncol. 1999;18:2a.
7. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995;13:2483-2489.
8. Ohno R. Recent progress in the treatment of adult acute leukemia. Jpn J Clin Oncol. 1989;52:1287-1293.
9. Ohno R. Multicenter cooperative study group in hematology in Japan: the 10-year history and role of the Japan Adult Leukemia Study Group in Japan. Int J Hematol. 1998;67:213-219.
10. Ohno R, Kobayashi T, Tanimoto M, et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer. 1993;71:3888-3895.
11. Kobayashi T, Miyawaki S, Tanimoto M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J Clin Oncol. 1996;14:204-213.
12. Miyawaki S, Tanimoto M, Kobayashi T, et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol. 1999;70:97-104.
13. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998;16:78-85.
14. Ohtake S, Miyawaki S, Tanimoto M, et al. Randomized clinical trial of response-oriented individualized versus fixed schedule induction chemotherapy in adult acute myeloid leukemia: the JALSG AML95 study [abstract]. Blood. 1999;94(suppl 1):298a.
15. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992;10:1103-1111.
16. Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313-319.
17. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666-1674.
18. Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N. All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood. 1994;84:3001-3009.
19. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340:994-1004.
20. Uzuka Y, Lion SK, Yamagata S. Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercatopurine and prednisolone: DCMP two-step therapy. Tohoku J Exp Med. 1976;118:212-225.
21. Cooperative Study Group on Leukemia and Allied Diseases. DCMP two-step therapy for acute myelogenous leukemia in adults. Jpn J Clin Oncol. 1978;8:133-140.
22. Ohno R, Kato Y, Nagura E, et al. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length. J Clin Oncol. 1986;4:1740-1747.
23. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710-1717.
24. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841-2851.
25. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996;87:4979-4989.